Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: A 5-year study of patients with hepatitis B with lamivudine resistance

Journal of Medical Virology

Volumn 84, Issue 10, 2012, Pages 1562-1570

  Ikeda, Fusao ^a   Baba, Nobuyuki ^b   Takaguchi, Koichi ^b   Kubota, Junichi ^c   Miyoshi, Kenji ^c   Fujioka, Shin Ichi ^d   Moritou, Yuki ^a   Takeuchi, Yasuto ^a   Yasunaka, Tetsuya ^a   Miyake, Yasuhiro ^a   Takaki, Akinobu ^a   Iwasaki, Yoshiaki ^a   Kobashi, Haruhiko ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c Tsuyama Central Hospital   (Japan)

^d OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

Author keywords

Adefovir; Hepatitis B virus; Lamivudine resistance

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG METABOLISM; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROPORTIONAL HAZARDS MODEL; TREATMENT RESPONSE;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 84865553110     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23371     Document Type: Article

References (30)

1. Beasley RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellularcarcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2:1129-1133.
2. Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R. 2007. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 47:366-372.
3. Deterding K, Naesens L, Buti M, Janssen H, Kirschner J, Guerrero A, Reijnders J, Neyts J, Zoulim F, Wedemeyer H. 2011. Adefovir serum levels do not differ between responders and non-responders. J Viral Hepat 18:e175-e178.
4. Fattovich G, Bortolotti F, Donato F. 2008. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 48:335-352.
5. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, Lok AS. 2011. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 53:1854-1863.
6. Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M, Ishikawa H, Masaki N, Seriu T, Omata M. 2010. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int 4:414-422.
7. Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. 2010. Rescue therapy for lamivudine-resistant chronic hepatitis B: Comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy, and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 25:1374-1380.
8. Kobayashi M, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kawamura Y, Suzuki Y, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, Kumada H. 2010. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res 40:125-134.
9. Kudo M. 1999. Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions. Semin Liver Dis 19:297-309.
10. Kurashige N, Hiramatsu N, Ohkawa K, Yakushijin T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Oshita M, Mita E, Hagiwara H, Nagase T, Yoshihara H, Hayashi E, Imai Y, Kato M, Kashihara T, Hayashi N. 2009. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol 44:601-607.
11. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36:687-696.
12. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. 2007. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451.
13. Lee YS, Chung YH, Kim JA, Jin YJ, Park WH, Kim SE, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Lee YS, Suh DJ. 2012. The rtL180M mutation of hepatitis B virus closely associates with frequent virologic resistance to adefovir dipivoxil therapy. J Gastroenterol Hepatol 27:300-305.
14. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, Pao CC. 1986. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 90:263-267.
15. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531.
16. Lok AS. 2007. Navigating the maze of hepatitis B treatments. Gastroenterology 132:1586-1594.
17. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442-2455.
18. Mitsui F, Tsuge M, Kimura T, Kitamura S, Abe H, Saneto H, Kawaoka T, Miki D, Hatakeyama T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Takahashi S, Hayes CN, Igarashi H, Morimoto K, Shimizu M, Chayama K. 2010. Importance of serum concentration of adefovir for lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother 54:3205-3211.
19. Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T, Shoji B, Takaki A, Iwasaki Y, Sakaguchi K, Shiratori Y, Yamamoto K. 2008. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol 23:794-803.
20. Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C. 1993. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: A comparison with HBV DNA testing. Hepatology 18: 1306-1312.
21. Peterson MS, Baron RL. 2001. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis 5:123-144.
22. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45:307-313.
23. Sugauchi F, Mizokami M, Orito E, Ohno T, Kato H, Suzuki S, Kimura Y, Ueda R, Butterworth LA, Cooksley WG. 2001. A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: Complete genome sequence and phylogenetic relatedness. J Gen Virol 82:883-892.
24. Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H. 2010. Efficacy of switching to entecavir monotherapy in Japanese lamivudinepretreated patients. J Gastroenterol Hepatol 25:892-898.
25. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA. 2010. Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51:1933-1944.
26. Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. 2008. Treatment recommendations for chronic hepatitis B: An evaluation of current guidelines based on a natural history study in the United States. Hepatology 48:1070-1078.
27. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F. 2008. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48:747-755.
28. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen DS, Chen CJ, Taiwan Community-Based Cancer Screening Project Group. 2002. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347:168-174.
29. Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. 2008. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Twoyear follow-up. J Hepatol 48:923-931.
30. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608.